Insider Selling: uniQure (NASDAQ:QURE) Director Sells $53,930.58 in Stock

uniQure N.V. (NASDAQ:QURE) Director Jeremy Springhorn sold 1,993 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the transaction, the director owned 43,251 shares of the company’s stock, valued at $1,170,372.06. This represents a 4.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

uniQure Stock Performance

NASDAQ:QURE opened at $27.57 on Monday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $22.52 and a two-hundred day moving average price of $21.76. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. As a group, research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on QURE. Barclays dropped their target price on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research report on Tuesday, May 5th. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. Finally, Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc lifted its position in uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after buying an additional 189,029 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in uniQure during the third quarter valued at approximately $6,281,000. Farallon Capital Management LLC lifted its position in uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after buying an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC acquired a new position in uniQure during the third quarter valued at approximately $8,599,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.